Does the Vitadio Health App Improve HbA1c in Type 2 Diabetes?
An unblinded randomized trial testing whether adding the Vitadio self-management app to standard care improves HbA1c in type 2 diabetes. PICO summary and expert commentary.
Hormone Insight Editorial Team
Clinical archive
Empagliflozin and Cardiac Reserve in Diabetic HFpEF: A Small Open-Label Mechanistic RCT
A single-centre, open-label randomised trial of empagliflozin 10 mg in 70 patients with type 2 diabetes and HFpEF found improved 6-minute walk distance and diastolic reserve markers. PICO summary and expert commentary.
Which is better for heart disease and diabetes: rosuvastatin with ezetimibe or higher-dose rosuvastatin?
A 223-patient randomised trial found single-pill rosuvastatin 10 mg plus ezetimibe was non-inferior, not superior, to rosuvastatin 20 mg for LDL-C lowering in ASCVD and type 2 diabetes. PICO summary and expert commentary.
DAPA ACT HF-TIMI 68: Rationale and Design of In-Hospital Dapagliflozin in Acute Heart Failure
Design paper for the DAPA ACT HF-TIMI 68 trial testing in-hospital dapagliflozin versus placebo in 2,401 patients with acute heart failure; no efficacy results are reported. PICO summary and expert commentary.
Does Empagliflozin Boost Red Blood Cell Production in Heart Failure?
A biomarker substudy of the EMPEROR program shows empagliflozin activates the erythropoietin-erythroferrone-hepcidin axis and raises haemoglobin in heart failure. PICO summary and expert commentary.
Hypoglycaemic Agents Plus a High-Protein Diet and Exercise for Type 2 Diabetes Remission: A Small RCT
A small single-centre randomised trial testing weight-lowering hypoglycaemic agents plus a high-protein diet and moderate exercise against standard care for diabetes remission in adults with obesity. PICO summary and expert commentary.
Do TZDs and SGLT2 Inhibitors Improve Liver Health in Type 2 Diabetes?
A 24-week open-label randomised trial testing pioglitazone plus empagliflozin versus monotherapy for fatty liver in type 2 diabetes. PICO summary and expert commentary.
Can AI Help Adjust Insulin in Real Time for Type 2 Diabetes?
A 149-patient inpatient randomized trial found an AI insulin titration system noninferior to senior physicians for time-in-range glucose control. PICO summary and expert commentary.
A Single HIIT Session Improves Endothelial Function More Than Moderate Exercise in Type 2 Diabetes
An acute randomised trial in 57 sedentary adults with type 2 diabetes found a single HIIT session raised flow-mediated dilation more than moderate continuous exercise, while both lowered post-exercise glucose. PICO summary and expert commentary.
PARTNER Study Protocol: Dapagliflozin Plus Continuous Ketone Monitoring to Reduce DKA Risk in Type 1 Diabetes (Design Only, No Results Yet)
The PARTNER study is a published trial protocol, not a results paper: it describes the rationale and design of a randomised crossover trial of dapagliflozin plus continuous ketone monitoring in type 1 diabetes, with no outcomes yet reported. PICO summary and expert commentary.